ACUTE AND LATE TOXICITY OF PELVIC RADIOTHERAPY AND CONCOMITANT HYPOFRACTIONATED IMRT BOOST COMBINED WITH HORMONAL THERAPY FOR HIGH-RISK PROSTATE CANCER

被引:0
|
作者
Quon, H. [1 ]
Loblaw, A. [1 ]
Morton, G. [1 ]
Sixel, K. [1 ]
Pang, G. [1 ]
Basran, P. [2 ]
Szumacher, E. [1 ]
Danjoux, C. [1 ]
Choo, R. [3 ]
Thomas, G. [1 ]
Kiss, A. [1 ]
Deabreu, A. [1 ]
Cheung, P. [1 ]
机构
[1] Univ Toronto, Toronto, ON, Canada
[2] Odette Canc Ctr, Toronto, ON, Canada
[3] Mayo Clin, Rochester, NY USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
143
引用
收藏
页码:S47 / S47
页数:1
相关论文
共 50 条
  • [41] Phase II trial of pelvic nodal irradiation with hypofractionated IMRT-SIB for high-risk prostate cancer
    Magli, A.
    Ceschia, T.
    Moretti, E.
    Signor, M.
    Polsinelli, M.
    Prisco, A.
    Crespi, M.
    Foti, C.
    Malisan, M. R.
    Fongione, S.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S91 - S91
  • [42] Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment
    Pervez, Nadeem
    Boychak, Alex
    Drodge, Claudia S.
    Yee, Don
    Le, Duc
    Murtha, Albert
    Parliament, Matthew
    Amanie, John
    Mihai, Alina
    Field, Colin
    Mackenzie, Marc
    Ghosh, Sunita
    Fallone, Gino
    Pearcey, Robert
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (02): : 200 - 206
  • [43] A Treatment Planning Study of Moderately Hypofractionated Intensity-Modulated Proton Therapy (IMPT) to the Prostate and Pelvic Combined with Extremely Hypofractionated IMPT Boost to Prostate with Urethral Dose Reduction for High-Risk Prostate Cancer
    Liu, S.
    Gao, X.
    Ma, M.
    Zhao, Z.
    Qin, S.
    Zhao, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E782 - E782
  • [44] Whole Pelvic RT with SBRT boost Versus IMRT for Patients with High-Risk Localised Prostate Cancer
    Wang, S. C.
    Ting, W. C.
    Chang, Y. C.
    Yang, C. C.
    Lin, Y. W.
    RADIOTHERAPY AND ONCOLOGY, 2019, 141 : S37 - S37
  • [45] Quality of life after pelvic radiotherapy with hypofractionated IMRT boost and long-term hormone therapy for locally advanced prostate cancer
    Quon, H. C.
    Cheung, P.
    Loblaw, D. A.
    Morton, G.
    Szumacher, E.
    Danjoux, C.
    Choo, R.
    Thomas, G.
    Kiss, A.
    Deabreu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [46] THE PILOT STUDY ON ACUTE AND LATE TOXICITY Of HYPOFRACTIONATED RADIOTHERAPY IN LOW-RISK PROSTATE CANCER PATIENTS
    zajusz, A.
    Behrendt, K.
    Nowicka, E.
    Gawkowska-Suwinska, M.
    Plewicki, G.
    Smolska, B.
    Glglok, M.
    Slosarek, K.
    Maciejewski, B.
    RADIOTHERAPY AND ONCOLOGY, 2009, 90 : S19 - S20
  • [47] Hypofractionated Simultaneous Integrated Boost IMRT in high risk prostate cancer - A novel approach
    Sashidharan, S.
    Beena, K.
    Chelakkot, P. G.
    Madhavan, R.
    Menon, D.
    Makuny, D.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S636 - S636
  • [48] Acute toxicity hypofractionated-IMRT vs standard radiotherapy in prostate cancer: comparative study
    Valero Albarran, J.
    Domingos da Silva, R. Guimaraes
    Payano, S.
    Montero, A.
    Sanchez, E.
    Chen, X.
    Hernando, O.
    Garcia Aranda, M.
    Ciervide, R.
    Lopez, M.
    Rubio, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S646 - S646
  • [49] DOSE ESCALATION WITH HYPOFRACTIONATED IMRT FOR PROSTATE CANCER: ACUTE TOXICITY
    Zilli, T.
    Molla, M.
    Rouzaud, M.
    Nouet, P.
    Wang, H.
    Dipasquale, G.
    Escude, L.
    Casanova, N.
    Linero, D.
    Miralbell, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (11) : 625 - 625
  • [50] Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer
    Lee, Tae Hoon
    Pyo, Hongryull
    Yoo, Gyu Sang
    Jeon, Seong Soo
    Seo, Seong Il
    Jeong, Byong Chang
    Jeon, Hwang Gyun
    Sung, Hyun Hwan
    Kang, Minyong
    Song, Wan
    Chung, Jae Hoon
    Bae, Bong Kyung
    Park, Won
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2024, 68 (03) : 333 - 341